^
    8d
    A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo (clinicaltrials.gov)
    P2, N=176, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    AiSuDa (ivarmacitinib)
    1m
    A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study on the Efficacy and Safety of JAK1 Inhibitor Ivarmacitinib in Combination with Topical Corticosteroids in the Treatment of Moderate-to-Severe Chronic Hand Eczema (ChiCTR2500109549)
    P4, N=80, Not yet recruiting, The First Hospital of Hebei Medical University; The First Hospital of Hebei Medical University
    New P4 trial
    |
    AiSuDa (ivarmacitinib)
    1m
    Ivarmacitinib for the Treatment of Sjögren’s Syndrome (ChiCTR2500108666)
    P4, N=30, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
    New P4 trial
    |
    AiSuDa (ivarmacitinib)
    1m
    Efficacy and Safety of Ivarmacitinib Sulfate Tablets in the Treatment of SAPHO Syndrome: A Single-Arm, Single-Center, Open-Label Clinical Trial (ChiCTR2500108339)
    P4, N=20, Not yet recruiting, The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University
    New P4 trial
    |
    AiSuDa (ivarmacitinib)
    4ms
    A Prospective, Multicenter Study on the Efficacy and Safety of Ivarmacitinib in the Treatment of Moderate-to-Severe Active Rheumatoid Arthritis(IMPROVE-RA) (ChiCTR2500106834)
    P4, N=1000, Not yet recruiting, Nanjing DrumTower Hospital of Nanjing University Medical School; Nanjing DrumTower Hospital of Nanjing University Medical School
    New P4 trial
    |
    CRP (C-reactive protein)
    |
    AiSuDa (ivarmacitinib)
    4ms
    JAK1 inhibitor combined with Camrelizumab as first-line therapy for PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma (ChiCTR2500106336)
    P2, N=30, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    AiRuiKa (camrelizumab) • AiSuDa (ivarmacitinib)
    4ms
    Efficacy and Safety of Ivarmacitinib in Patients with Polymyalgia Rheumatica: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study (ChiCTR2500105703)
    P4, N=80, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New P4 trial
    |
    AiSuDa (ivarmacitinib)
    4ms
    A Multi-Center, Randomized, Controlled Trial of Ivarmacitinib in IgG4-Related Disease (ChiCTR2500105444)
    P4, N=88, Not yet recruiting, Beijing Friendship Hospital Affiliated to Capital Medical University; Beijing Friendship Hospital Affiliated to Capital Medical University
    New P4 trial
    |
    AiSuDa (ivarmacitinib)
    4ms
    A prospective phase II clinical trial evaluating the efficacy and safety of chemotherapy combined with immune checkpoint inhibitors and ivarmacitinib in first-line treatment of extensive stage small cell lung cancer (ChiCTR2500104514)
    P2, N=30, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial • Checkpoint inhibition
    |
    AiSuDa (ivarmacitinib)
    4ms
    A prospective clinical study on advanced or metastatic non-small cell lung cancer in the first-line treatment of adebelimab combined with emacetinib +/- chemotherapy (ChiCTR2500103941)
    P4, N=68, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New P4 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiRuiLi (adebrelimab) • AiSuDa (ivarmacitinib)
    4ms
    A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Pharmacokinetic Profile of Single and Multiple Dose Escalation Topical Dermal Administration of SHR0302 Alkali Gel in Healthy Subjects (clinicaltrials.gov)
    P1, N=32, Completed, Jiangsu HengRui Medicine Co., Ltd.
    New P1 trial
    |
    AiSuDa (ivarmacitinib)
    6ms
    Ivarmacitinib Sulfate: First Approval. (PubMed, Drugs)
    In April 2025, ivarmacitinib was approved in China for use in adult patients with moderate to severe atopic dermatitis (AD) who have had an inadequate response or intolerance to topical or other systemic treatments. This article summarizes the milestones in the development of ivarmacitinib leading to this first approval for the treatment of adult patients with active AS.
    Journal
    |
    JAK1 (Janus Kinase 1)
    |
    AiSuDa (ivarmacitinib)